113 related articles for article (PubMed ID: 38760099)
1. B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases.
Haghikia A; Schett G; Mougiakakos D
Lancet Neurol; 2024 Jun; 23(6):615-624. PubMed ID: 38760099
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
Hunter BD; Rogalski M; Jacobson CA
Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
[No Abstract] [Full Text] [Related]
4. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
5. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.
Marofi F; Rahman HS; Achmad MH; Sergeevna KN; Suksatan W; Abdelbasset WK; Mikhailova MV; Shomali N; Yazdanifar M; Hassanzadeh A; Ahmadi M; Motavalli R; Pathak Y; Izadi S; Jarahian M
Front Immunol; 2021; 12():681984. PubMed ID: 34248965
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases.
Lyu X; Gupta L; Tholouli E; Chinoy H
Rheumatology (Oxford); 2024 May; 63(5):1206-1216. PubMed ID: 37982747
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
8. Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease.
Daamen AR; Lipsky PE
Ann Rheum Dis; 2024 May; 83(6):696-699. PubMed ID: 38637134
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
Strati P; Neelapu SS
Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
[TBL] [Abstract][Full Text] [Related]
10. CAR-T Cell-Mediated B-Cell Depletion in Central Nervous System Autoimmunity.
Gupta S; Simic M; Sagan SA; Shepherd C; Duecker J; Sobel RA; Dandekar R; Wu GF; Wu W; Pak JE; Hauser SL; Lim W; Wilson MR; Zamvil SS
Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36657993
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future.
Li L; Zhu X; Qian Y; Yuan X; Ding Y; Hu D; He X; Wu Y
Front Immunol; 2020; 11():594271. PubMed ID: 33224149
[TBL] [Abstract][Full Text] [Related]
12. Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies.
Song MK; Park BB; Uhm JE
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31658644
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
[TBL] [Abstract][Full Text] [Related]
14. CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
Ghosh A; Mailankody S; Giralt SA; Landgren CO; Smith EL; Brentjens RJ
Leuk Lymphoma; 2018 Sep; 59(9):2056-2067. PubMed ID: 29105517
[TBL] [Abstract][Full Text] [Related]
15. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
16. The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice.
Cerrano M; Ruella M; Perales MA; Vitale C; Faraci DG; Giaccone L; Coscia M; Maloy M; Sanchez-Escamilla M; Elsabah H; Fadul A; Maffini E; Pittari G; Bruno B
Front Immunol; 2020; 11():888. PubMed ID: 32477359
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes.
Khvorost D; Kendall B; Jazirehi AR
Cells; 2024 Apr; 13(8):. PubMed ID: 38667277
[TBL] [Abstract][Full Text] [Related]
18. CAR T-Cell Therapy in Hematological Malignancies.
Haslauer T; Greil R; Zaborsky N; Geisberger R
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
[TBL] [Abstract][Full Text] [Related]
19. CAR T-cell therapy in autoimmune diseases.
Schett G; Mackensen A; Mougiakakos D
Lancet; 2023 Nov; 402(10416):2034-2044. PubMed ID: 37748491
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
